{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:09Z","timestamp":1782276429350,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dld.2025.04.045","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:28:29Z","timestamp":1747380509000},"page":"1752-1760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A systematic review and meta-analysis of randomized controlled trials: the role of potassium-competitive acid blockers in endoscopy-negative reflux disease"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6671-0929","authenticated-orcid":false,"given":"Thai Hau","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Fass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dld.2025.04.045_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1756283X16681701","article-title":"The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease","volume":"10","author":"Fass","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2025.04.045_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","article-title":"Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics","volume":"41","author":"Fass","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2025.04.045_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/apt.16477","article-title":"Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease","volume":"54","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dld.2025.04.045_bib0004","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.cgh.2020.03.057","article-title":"Untangling nonerosive reflux disease from functional heartburn","volume":"19","author":"Patel","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2025.04.045_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/nyas.13845","article-title":"Nonerosive reflux disease: clinical concepts","volume":"1434","author":"Gyawali","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.dld.2025.04.045_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/653989","article-title":"Current advances in the diagnosis and treatment of nonerosive reflux disease","volume":"2013","author":"Chen","year":"2013","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"10.1016\/j.dld.2025.04.045_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"issue":"10","key":"10.1016\/j.dld.2025.04.045_bib0008","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/ctg.2015.39","article-title":"Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease?","volume":"6","author":"Hunt","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2025.04.045_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"10.1016\/j.dld.2025.04.045_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/00325481.2024.2320081","article-title":"Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori","volume":"136","author":"Antequera","year":"2024","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.dld.2025.04.045_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5056\/jnm.2010.16.1.8","article-title":"Nonerosive reflux disease (NERD) - an update","volume":"16","author":"Hershcovici","year":"2010","journal-title":"J Neurogastroenterol Motil"},{"issue":"28","key":"10.1016\/j.dld.2025.04.045_bib0012","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3748\/wjg.v28.i28.3608","article-title":"Potassium-competitive acid blockers and gastroesophageal reflux disease","volume":"28","author":"Leowattana","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.dld.2025.04.045_bib0013","article-title":"Comparison of potassium-competitive acid blockers and proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Agago","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.dld.2025.04.045_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","volume":"22","author":"Laine","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2025.04.045_bib0015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/apt.17728","article-title":"Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease","volume":"58","author":"Fass","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.dld.2025.04.045_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102373","article-title":"Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: a systematic review and meta-analysis","author":"Bandyopadhyay","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2025.04.045_bib0017","first-page":"154","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"35","author":"Higgins","year":"2014","journal-title":"Online Kensaku"},{"issue":"7","key":"10.1016\/j.dld.2025.04.045_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.dld.2025.04.045_bib0019","series-title":"Version endnote 20","year":"2013"},{"key":"10.1016\/j.dld.2025.04.045_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.dld.2025.04.045_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-6-31","article-title":"The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials","volume":"6","author":"Shaw","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.dld.2025.04.045_bib0022","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5056\/jnm18085","article-title":"Development and psychometric assessment of a self-evaluation questionnaire for gastroesophageal reflux disease","volume":"24","author":"Jung","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"issue":"9","key":"10.1016\/j.dld.2025.04.045_bib0023","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1542-3565(04)00348-9","article-title":"Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders","volume":"2","author":"Revicki","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2025.04.045_bib0024","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s11136-004-8751-3","article-title":"Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL","volume":"13","author":"de la Loge","year":"2004","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.dld.2025.04.045_bib0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.2010.04385.x","article-title":"The development and validation of a nocturnal gastro-oesophageal reflux disease symptom severity and impact questionnaire for adults","volume":"32","author":"Spiegel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2025.04.045_bib0026","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"10","key":"10.1016\/j.dld.2025.04.045_bib0027","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.dld.2025.04.045_bib0028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.dld.2025.04.045_bib0029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019","journal-title":"Cochrane Handb Systematic Rev Interv"},{"key":"10.1016\/j.dld.2025.04.045_bib0030","series-title":"Review manager 5 (RevMan 5). version 5.4","year":"2020"},{"issue":"7","key":"10.1016\/j.dld.2025.04.045_bib0031","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Global Spine J"},{"key":"10.1016\/j.dld.2025.04.045_bib0032","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)","author":"Higgins","year":"2019","journal-title":"Cochrane"},{"key":"10.1016\/j.dld.2025.04.045_bib0033","first-page":"343","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.dld.2025.04.045_bib0034","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000101","article-title":"Efficacy and safety of Vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study","volume":"10","author":"Kinoshita","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"10.1016\/j.dld.2025.04.045_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the efficacy and safety of Vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study","volume":"81-82","author":"Kinoshita","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"issue":"11","key":"10.1016\/j.dld.2025.04.045_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","volume":"22","author":"Laine","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T08:35:27Z","timestamp":1756110927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825007558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1590865825007558"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.045","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of randomized controlled trials: the role of potassium-competitive acid blockers in endoscopy-negative reflux disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}